Analysis of the array revealed a gradual increase of cells expressing CD95 from the primary tumour (13.2%) to the metastatic lesions in the lymph node (26.3%) and liver (44.5%), suggesting that CD95 has a role during PDAC metastatic progression (Figure 4a). This evidence concerns the gene FAS and neoplasm.